Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 537-552

  Boone, Brian A ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Damage associated molecular pattern molecules; DAMP receptors; DAMPs; HMGB1; RAGE; S100

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTINEOPLASTIC AGENT; CATHELICIDIN; DAMAGE ASSOCIATED MOLECULAR PATTERN MOLECULE; DAMP RECEPTOR; DEFENSIN; GALECTIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; KIDNEY INJURY MOLECULE 1; NUCLEOLIN; PROTEIN; PROTEIN S100B; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; QUERCETIN; RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; INNATE IMMUNITY; MELANOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR MICROENVIRONMENT;

HUMANS; MELANOMA; RECEPTORS, PATTERN RECOGNITION; SKIN NEOPLASMS;

EID: 84891793242     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_29     Document Type: Article

References (79)

1. Matzinger P (2002) The danger model: A renewed sense of self. Science 296:301-305
2. Lotze MT, Zeh HJ, Rubartelli A et al (2007) The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220:60-81
3. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111-1122
4. Leclerc E, Fritz G, Vetter SW, Heizmann CW (2009) Binding of S100 proteins to RAGE: An update. Biochim Biophys Acta 1793: 993-1007
5. Ilg EC, Schafer BW, Heizmann CW (1996) Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer 68: 325-332
6. Maelandsmo GM, Florenes VA, Mellingsaeter T et al (1997) Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 74:464-469
7. Helfman DM, Kim EJ, Lukanidin E, Grigorian M (2005) The metastasis associated protein S100A4: Role in tumour progression and metastasis. Br J Cancer 92:1955-1958
8. Baudier J, Delphin C, Grunwald D et al (1992) Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc Natl Acad Sci U S A 89:11627-11631
9. Lin J, Yang Q, Wilder PT et al (2010) The calcium-binding protein S100B downregulates p53 and apoptosis in malignant melanoma. J Biol Chem 285:27487-27498
10. Lin J, Yang Q, Yan Z et al (2004) Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem 279: 34071-34077
11. Markowitz J, Chen I, Gitti R et al (2004) Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem 47:5085-5093
12. Smith J, Stewart BJ, Glaysher S et al (2010) The effect of pentamidine on melanoma ex vivo. Anticancer Drugs 21:181-185
13. deBlacam C, Byrne C, Hughes E et al (2011) HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: New targets for the kinase inhibitor dasatinib. Br J Cancer 105: 118-123
14. Eustace AJ, Crown J, Clynes M, O'Donovan N (2008) Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 6:53
15. Kluger HM, Dudek AZ, McCann C et al (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202-2208
16. Hofmeister-Mueller V, Vetter-Kauczok CS, Ullrich R et al (2009) Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients. Cancer Immunol Immunother 58:1265-1273
17. Hegyi Z, Zwicker S, Bureik D et al (2012) Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinfl ammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol 132:1416-1424
18. Godar DE, Landry RJ, Lucas AD (2009) Increased UVA exposures and decreased cutaneous vitamin D(3) levels may be responsible for the increasing incidence of melanoma. Med Hypotheses 72:434-443
19. Goodwin GH, Johns EW (1977) The isolation and Purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol 16:257-267
20. Tang D, Kang R, Zeh HJ 3rd, Lotze MT (2011) High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 14:1315-1335
21. Tang D, Kang R, Zeh HJ 3rd, Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799:131-140
22. Ito N, DeMarco RA, Mailliard RB et al (2007) Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81:75-83
23. Perez RP, Zhang P, Bosserhoff AK et al (2000) Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens. Hum Pathol 31:1381-1388
24. Poser I, Golob M, Buettner R, Bosserhoff AK (2003) Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998
25. Dong Xda E, Ito N, Lotze MT et al (2007) High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy. J Immunother 30:596-606
26. Pasheva EA, Ugrinova I, Spassovska NC, Pashev IG (2002) The binding affi nity of HMG1 protein to DNA modifi ed by cis-platin and its analogs correlates with their antitumor activity. Int J Biochem Cell Biol 34:87-92
27. Ulloa L, Ochani M, Yang H et al (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic infl ammation. Proc Natl Acad Sci U S A 99:12351-12356
28. Muller AJ, DuHadaway JB, Jaller D et al (2010) Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 70:1845-1853
29. Tang D, Kang R, Xiao W et al (2009) Quercetin prevents LPS-induced high-mobility group box 1 release and proinfl ammatory function. Am J Respir Cell Mol Biol 41:651-660
30. Rosner K, Ropke C, Pless V, Skovgaard GL (2006) Late type apoptosis and apoptosis free lethal effect of quercetin in human melanoma. Biosci Biotechnol Biochem 70:2169-2177
31. Camby I, Le Mercier M, Lefranc F, Kiss R (2006) Galectin-1: A small protein with major functions. Glycobiology 16:137R-157R
32. Vereecken P, Debray C, Petein M et al (2005) Expression of galectin-3 in primary and metastatic melanoma: Immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 296:353-358
33. Le QT, Shi G, Cao H et al (2005) Galectin-1: A link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23:8932-8941
34. Lefranc F, Mathieu V, Kiss R (2011) Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem 2:193-201
35. Mourad-Zeidan AA, Melnikova VO, Wang H et al (2008) Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 173:1839-1852
36. Inohara H, Raz A (1994) Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11:527-532
37. Platt D, Raz A (1992) Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84:438-442
38. Nangia-Makker P, Hogan V, Honjo Y et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modifi ed citrus pectin. J Natl Cancer Inst 94: 1854-1862
39. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem Sci 31:164-172
40. Shipp C, Weide B, Derhovanessian E, Pawelec G (2012) Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters. Cell Stress Chaperones 18(2):145-154
41. Ciocca DR, Cayado-Gutierrez N, Maccioni M, Cuello-Carrion FD (2012) Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med 12(9):1183-1197
42. Pilla L, Patuzzo R, Rivoltini L et al (2006) A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 55:958-968
43. Testori A, Richards J, Whitman E et al (2008) Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 26:955-962
44. Liu KS, Ding WC, Wang SX et al (2012) The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo. Oncol Rep 27:1904-1910
45. Ohshima Y, Tsukimoto M, Takenouchi T et al (2010) gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta 1800: 40-46
46. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75:39-48
47. Kim JE, Kim HJ, Choi JM et al (2010) The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol 163:959-967
48. Territo MC, Ganz T, Selsted ME, Lehrer R (1989) Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 84:2017-2020
49. Fernandez LP, Milne RL, Pita G et al (2009) Human beta-defensins (HBD1 and HBD3) and malignant melanoma susceptibility. Melanoma Res 19:340-341
50. Mei HF, Jin XB, Zhu JY et al (2012) Betadefensin 2 as an adjuvant promotes antimelanoma immune responses and inhibits the growth of implanted murine melanoma in vivo. PLoS One 7:e31328
51. Abdelmohsen K, Gorospe M (2012) RNAbinding protein nucleolin in disease. RNA Biol 9(6):799-808
52. Mourmouras V, Cevenini G, Cosci E et al (2009) Nucleolin protein expression in cutaneous melanocytic lesions. J Cutan Pathol 36: 637-646
53. Sparvero LJ, Asafu-Adjei D, Kang R et al (2009) RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and infl ammation. J Transl Med 7:17
54. Eichmuller S, Usener D, Jochim A, Schadendorf D (2002) mRNA expression of tumorassociated antigens in melanoma tissues and cell lines. Exp Dermatol 11:292-301
55. Leclerc E, Heizmann CW, Vetter SW (2009) RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen Physiol Biophys 28 Spec No Focus:F65-F75
56. Masaki H, Okano Y, Sakurai H (1999) Generation of active oxygen species from advanced glycation end-products (AGEs) during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damaging. Biochim Biophys Acta 1428:45-56
57. Abe R, Shimizu T, Sugawara H et al (2004) Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 122:461-467
58. Raucci A, Cugusi S, Antonelli A et al (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22: 3716-3727
59. Taguchi A, Blood DC, del Toro G et al (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354-360
60. Arumugam T, Ramachandran V, Gomez SB et al (2012) S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res 18:4356-4364
61. Zhu C, Anderson AC, Schubart A et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245-1252
62. Chiba S, Baghdadi M, Akiba H et al (2012) Tumor-infiltrating DCs suppress nucleic acidmediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 13:832-842
63. Wiener Z, Kohalmi B, Pocza P et al (2007) TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 127:906-914
64. Wu FH, Yuan Y, Li D et al (2010) Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway. Oncol Rep 24:693-699
65. Fourcade J, Sun Z, Benallaoua M et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186
66. Yu M, Wang H, Ding A et al (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179
67. Park JS, Svetkauskaite D, He Q et al (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279:7370-7377
68. Saint-Jean M, Knol AC, Nguyen JM et al (2011) TLR expression in human melanoma cells. Eur J Dermatol 21:899-905
69. Yu N, Zhang S, Zuo F et al (2009) Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9. J Dermatol Sci 56: 113-120
70. Mittal D, Saccheri F, Venereau E et al (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29:2242-2252
71. Matijevic T, Pavelic J (2010) Toll-like receptors: Cost or benefi t for cancer? Curr Pharm Des 16:1081-1090
72. Huang B, Zhao J, Unkeless JC et al (2008) TLR signaling by tumor and immune cells: A double-edged sword. Oncogene 27:218-224
73. Nunez NG, Andreani V, Crespo MI et al (2012) IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res 72:592-603
74. Tittarelli A, Gonzalez FE, Pereda C et al (2012) Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother 61(11):2067-2077
75. Zhu XM, Yao YM, Liang HP et al (2011) High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4. Cytokine 54: 296-304
76. Pashenkov M, Goess G, Wagner C et al (2006) Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716-5724
77. Yang HZ, Cui B, Liu HZ et al (2009) Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 4:e6520
78. Yan J, Hua F, Liu HZ et al (2012) Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice. Acta Pharmacol Sin 33:503-512
79. Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in infl ammation and cancer. Annu Rev Immunol 28:367-388